KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Revenue: 2009-2024

Historic Revenue for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $682.2 million.

  • Novavax's Revenue fell 16.64% to $70.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 13.02%. This contributed to the annual value of $682.2 million for FY2024, which is 30.65% down from last year.
  • Novavax's Revenue amounted to $682.2 million in FY2024, which was down 30.65% from $983.7 million recorded in FY2023.
  • In the past 5 years, Novavax's Revenue registered a high of $2.0 billion during FY2022, and its lowest value of $475.6 million during FY2020.
  • For the 3-year period, Novavax's Revenue averaged around $1.2 billion, with its median value being $983.7 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first spiked by 2,448.48% in 2020, then slumped by 50.36% in 2023.
  • Yearly analysis of 5 years shows Novavax's Revenue stood at $475.6 million in 2020, then soared by 141.02% to $1.1 billion in 2021, then surged by 72.89% to $2.0 billion in 2022, then slumped by 50.36% to $983.7 million in 2023, then slumped by 30.65% to $682.2 million in 2024.